Global Attention Deficit Hyperactivity Disorder Market 2025–2029: Unveiling Growth Developments with the Latest Updates
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Attention Deficit Hyperactivity Disorder Market Today And What Is Its Future Size?
The market for attention deficit hyperactivity disorder (ADHD) has seen significant growth in recent times. From being valued at $16.29 billion in 2024, it is projected to escalate to $17.38 billion in 2025, at a compound annual growth rate (CAGR) of 6.7%. The factors contributing to the growth during the historic period include an increased prevalence of ADHD, a heightened occurrence of the disorder in children, a rise in ADHD awareness, amplification in healthcare spending, and governmental efforts to increase awareness about mental health.
The market size for attention deficit hyperactivity disorder is projected to experience robust expansion in the upcoming years, reaching $22.42 billion in 2029 with a compound annual growth rate (CAGR) of 6.6%. The escalation during the forecast period can be ascribed to the rising number of kids and adults undergoing treatment, superior healthcare systems, the surge in personalized medicine, greater recognition of mental health disorders, and heightened usage of additives and preservatives in children’s meals. The forecast period will features trends such as upgrades in technology and inventive treatments, advancements in diagnosis and therapy techniques, the invention of new therapeutic drugs, a transition towards non-stimulant drugs, and forward strides in pharmaceutical treatments.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21108&type=smp
Which Demand Drivers Are Strengthening The Attention Deficit Hyperactivity Disorder Market?
The increasing utilization of personalized medicine is predicted to boost the expansion of the attention deficit hyperactivity disorder (ADHD) market. This medical approach personalizes treatments based on a person’s genetics, environment, and lifestyle aspects, resulting in more accurate and efficient healthcare. The use of personalized medicine is due to advancements in genomic technologies, facilitating the development of treatments aligned with an individual’s genetic profile leading to more targeted and efficient therapies. The significant contribution of ADHD to personalized medicine enables custom treatment strategies that cater to a person’s specific genetic, environmental, and behavioral traits, resulting in improved and targeted interventions. For example, according to a February 2024 report by the Personalized Medicine Coalition (PMC), a non-profit organization in the US, personalized medicines made up over one-third of new FDA drug approvals for the fourth year in a row in 2023. The FDA approved 16 new personalized treatments for rare diseases (a rise from 6 in 2022), 7 cancer drugs, and 3 for other conditions. Therefore, the increasing implementation of personalized medicine is fueling the expansion of the ADHD market.
Which Segment Accounts For The Largest Share In The Attention Deficit Hyperactivity Disorder Market?
The attention deficit hyperactivity disordermarket covered in this report is segmented –
1) By Type: Stimulants; Non-Stimulants
2) By Age Group: Children; Adults
3) By Gender: Male; Female
4) By Dosage Form: Tablets; Capsules; Other Dosage Forms
5) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
Subsegments:
1) By Stimulants: Methylphenidate-based Medications; Amphetamine-based Medications; Mixed Amphetamine Salts; Dexmethylphenidate
2) By Non-Stimulants: Atomoxetine (Strattera); Guanfacine (Intuniv); Clonidine (Kapvay); Bupropion (Wellbutrin)
What Strategic Shifts And Innovations Are Influencing The Attention Deficit Hyperactivity Disorder Market?
Key pharmaceutical companies within the ADHD market are shifting focus towards the creation of innovative drugs like extended-release tablets. These are designed to enhance treatment efficacy, boost patient adherence, and provid prolonged symptom control. Extended-release tablets gradually release the drug over time, providing steady symptom control throughout the day with just one dose. This lessens the need for multiple doses thus increasing convenience and adherence to the treatment regimen for ADHD patients. For example, JAMP Pharma Group, a pharmaceutical firm from Canada, introduced Guanfacine XR, a generic variant of INTUNIV XR by Takeda Canada Inc., a brand-name drug to treat ADHD, in February 2022. Guanfacine XR is a long-acting form of guanfacine that functions by impacting specific brain receptors to improve attention, control impulsive behavior, and reduce hyperactivity. It comes in various strengths (1 mg, 2 mg, 3 mg, and 4 mg) and is available in a 100-count bottle, offering versatility in treatment.
Which Companies Hold A Competitive Edge In The 1353 Market?
Major companies operating in the attention deficit hyperactivity disorder market are Pfizer Inc., Johnson & Johnson, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Neos Therapeutics Inc., Collegium Pharmaceutical Inc., Mallinckrodt Pharmaceuticals plc, Tris Pharma Inc., Arbor Pharmaceuticals LLC, Akili Interactive Labs Inc., Mind Medicine (MindMed) Inc., NeuroSigma Inc., KemPharm Inc., RespireRx Pharmaceuticals Inc., Cingulate Therapeutics LLC, Adlon Therapeutics L.P.
Access The Complete Report Here:
Which Region Is Forecasted To Lead The Attention Deficit Hyperactivity Disorder Market In The Coming Years?
North America was the largest region in the attention deficit hyperactivity disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21108&type=smp
Browse Through More Reports Similar to the Global Attention Deficit Hyperactivity Disorder Market 2025, By The Business Research Company
Attention Deficit Hyperactivity Disorder Adhd Therapeutics Global Market Report 2025
Myeloproliferative Disorders Drugs Global Market Report 2025
Hyperpigmentation Disorder Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
